Context Therapeutics
CNTX
20 hedge funds and large institutions have $6.32M invested in Context Therapeutics in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 4 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
25% more funds holding
Funds holding: 16 → 20 (+4)
4.62% more ownership
Funds ownership: 18.19% → 22.81% (+4.6%)
0% more capital invested
Capital invested by funds: $6.3M → $6.32M (+$16K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$2.23M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$736K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$236K |
| 4 |
AAA
Affinity Asset Advisors
New York
|
+$199K |
| 5 |
VF
Virtu Financial
New York
|
+$87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.53M |
| 2 |
Renaissance Technologies
New York
|
-$44K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$40K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$37.7K |
| 5 |
BlackRock
New York
|
-$37K |
CNTX Hedge Fund Activity: Q2 2022 in Review
20 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q2 2022, worth a combined $6.32M — up 0.25% from $6.3M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CNTX positions and 4 closed out — a net gain of 4 holders — while 5 added to existing stakes and 1 trimmed.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $2.23M. The largest seller was Sabby Management, exiting entirely with an estimated $2.53M sold.
- 20 institutional investors held Context Therapeutics (CNTX) as of Q2 2022, up from 16 in Q1 2022.
- Funds reported $6.32M of Context Therapeutics stock for Q2 2022, up 0.25% quarter-over-quarter.
- 8 funds opened new Context Therapeutics positions in Q2 2022 and 4 closed out, a net change of +4 holders.
- The largest Context Therapeutics buyer in Q2 2022 was AIGH Capital Management, an estimated $2.23M added.
- The largest Context Therapeutics seller in Q2 2022 was Sabby Management, an estimated $2.53M sold.
Based on aggregated 13F filings for Q2 2022.